BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16321823)

  • 1. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.
    Pratt G; Mead GP; Godfrey KR; Hu Y; Evans ND; Chappell MJ; Lovell R; Bradwell AR
    Leuk Lymphoma; 2006 Jan; 47(1):21-8. PubMed ID: 16321823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
    Caillon H; Avet-Loiseau H; Attal M; Moreau P; Decaux O; Dejoie T
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e228-e237. PubMed ID: 30799237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
    Mösbauer U; Ayuk F; Schieder H; Lioznov M; Zander AR; Kröger N
    Haematologica; 2007 Feb; 92(2):275-6. PubMed ID: 17296589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.
    Barley K; Tindle S; Bagiella E; Jagannath S; Chari A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):541-5. PubMed ID: 26119495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R
    Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease].
    Honma R; Fukase S; Suzuki M; Omoto E
    Rinsho Ketsueki; 2010 Apr; 51(4):270-4. PubMed ID: 20467224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
    Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
    Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
    Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
    San Miguel JF; Lahuerta JJ; García-Sanz R; Alegre A; Bladé J; Martinez R; García-Laraña J; De La Rubia J; Sureda A; Vidal MJ; Escudero A; Pérez-Esquiza E; Conde E; García-Ruiz JC; Cabrera R; Caballero D; Moraleda JM; Leon A; Besalduch J; Hernandez MT; Rifon J; Hernandez F; Solano C; Palomera L; Parody R; Gonzalez JD; Mataix R; Maldonado J; Constela J; Carrera D; Bello JL; De Pablos JM; Pérez-Simón JA; Torres JP; Olanguren J; Prieto E; Acebede G; Peñarrubia MJ; Torres P; Díez-Martín JL; Rivas A; Sánchez JM; Díaz-Mediavilla J
    Hematol J; 2000; 1(1):28-36. PubMed ID: 11920166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.
    Campbell JP; Heaney JL; Shemar M; Baldwin D; Griffin AE; Oldridge E; Goodall M; Afzal Z; Plant T; Cobbold M; Jefferis R; Jacobs JF; Hand C; Drayson MT
    Clin Chem Lab Med; 2017 Mar; 55(3):424-434. PubMed ID: 27505089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.